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Abstract: Tourette syndrome (TS) is a childhood neurobehavioural disorder, characterised by the
presence of motor and vocal tics, typically starting in childhood but persisting in around 20% of
patients into adulthood. In those patients who do not respond to pharmacological or behavioural
therapy, deep brain stimulation (DBS) may be a suitable option for potential symptom improvement.
This manuscript attempts to summarise the outcomes of DBS at different targets, explore the possible
mechanisms of action of DBS in TS, as well as the potential of adaptive DBS. There will also be a focus
on the future challenges faced in designing optimized trials.
Keywords: Tourette syndrome; TS deep brain stimulation; DBS
1. Introduction
Tourette syndrome (TS) is a childhood neurobehavioural disorder affecting approximately
0.3%–0.8% of the paediatric population [1]. It is defined by the presence of at least one vocal and
two motor tics starting before the age of 18, lasting longer than one year, with the exclusion of other
causes [2]. Tics are often preceded by a premonitory urge [3] tend to occur daily in variable bouts
and follow a waxing and waning course. The typical age of onset is five to seven years [4] with
symptoms peaking at puberty and often remitting into early adulthood. In around 20% of patients,
symptoms persist and have a detrimental effect on quality of life including social, professional and
educational development [5]. Psychiatric co-morbidities are experienced in approximately 50%–90% of
TS individuals, particularly obsessive compulsive disorder (OCD/OCB), attention deficit hyperactivity
disorder (ADHD), deliberate self-injurious behaviours (SIBs) along with disturbances in mood and
anxiety [6]. Current treatments include a combination of pharmacological and behavioural therapies.
However, in patients with disabling refractory symptoms, surgical intervention, such as deep brain
stimulation (DBS), may be considered a potential option for symptom improvement.
DBS has been applied to patients with both hypokinetic and hyperkinetic movement disorders
including Parkinson’s disease, dystonia and essential tremor, as well as neuropsychiatric disorders
such as treatment-resistant depression and OCD [7]. Targets of DBS for TS are based on the postulated
dysfunction of the basal ganglia-thalamo-cortical loops. A simplistic proposal is that aberrant activity
in groups of striatal medium spiny neurons [8] lead to a decrease in the inhibitory output of the globus
pallidus internus (GPi), resulting in disinhibition and the execution of involuntary cortical motor
commands in the form of repetitive, stereotyped movements. A variety of methods, such as structural
imaging in longitudinal studies of TS patients, have correlated smaller caudate nucleus volumes with
severity of tics, as well as changes in the diffusivity of water molecules in the frontal lobe and thalamus
as measured by diffusion tensor magnetic resonance imaging [9]. Decreased connectivity between
Brain Sci. 2016, 6, 35; doi:10.3390/brainsci6030035 www.mdpi.com/journal/brainsci
Brain Sci. 2016, 6, 35 2 of 19
caudate nucleus and lateral frontal cortex has been observed, supporting a cortical disinhibition
theory for the disorder [10] though contradictory findings have also been reported [11] and the precise
pathophysiology of TS remains unknown.
The current manuscript attempts to provide an updated review of the published literature
regarding the use of DBS for severe, medication refractory Tourette syndrome. A particular focus has
been (1) to understand the potential mechanisms of action of this therapy based on neurophysiological
recordings and neuroanatomical knowledge of the basal ganglia circuity; and (2) to make
recommendations for the future evaluation of the use of DBS in TS.
2. Methods
A broad search was carried out using the databases Pubmed and OVID Medline with a variety
of terms including “Tourette syndrome“, “GTS“, combined with “deep brain stimulation“ or “DBS“.
Each target region for DBS, including the “thalamus“ “globus pallidus internus“ “anterior limb internal
capsule“ “nucleus accumbens“, “globus pallidus externus“ were combined with the above terms.
Only references in the English language were included.
3. Literature Review
Currently, nine targets have been used in DBS for TS, including the thalamic centromedian
parafascicular complex (CMPf), the cross point of the centromedian nucleus-substantia
periventricularis-nucleus ventro-oralis nucleus (CM-Spv-Voi), the target of the nucleus ventro-oralis
posterior-ventro oralis anterior-Voi complex (Vop-Voa-Voi), the globus pallidus internus (GPi)
(anteromedial AND posteroventral regions), the nucleus accumbens (NA), the anterior limb of the
internal capsule (ALIC), the subthalamic nucleus (STN) and the globus pallidus externus (GPe) [12].
Known connections between nuclei targeted by TS DBS, as well as other structures in the cortico-basal
ganglia network are illustrated in Figure 1.
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Figure 1. Simplified schematic sho ing the ain connections of the cortico-thalamo-cortical network,
with the nuclei targeted in TS DBS in blue boxes (NA = nucleus accumbens, ALIC = anterior limb internal
capsule, CMPf centromedian parafasciular complex, CM Sp Voi, centromedian nucleus-substantia
periventricularis-nucleus ventro-oralis nucleus, the nucleus ventro-oralis posterior-ventro oralis anterior
ventro-oralis complex (Vop-Voa-Voi), GPe = globus pallidus externus, STN = subthalamic nucleus, GPi
(am, pv = anteromedial, posteroventral globus pallidus internus). The direct pathway is shown with
black arrows, the indirect pathway with grey arrows and other connections shown with blue arrows.
Projections from the primary motor cortex (M1), the pre-motor cortex (PMC) and the supplementary
motor area (SMA) are predominantly directed to the dorsal striatum (putamen and caudate) whereas
fibers from the prefrontal cortex (PFC) including the orbitofrontal cortex (OFC), ventromedial PFC
(vmPFC) and the dorsal PFC (dPFC) as well as the anterior cingulate cortex (ACC) mostly project to
the ventral striatum (nucleus accumbens and rostroventral most aspects of caudate and putamen).
The main output nuclei are the GPi and the substantia nigra pars reticulata (SNR). Other regions, such
as the substantia nigra pars compacta (SNC), also have connections with the striatum.
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The rationale behind target choice has varied depending on whether tics are considered
a movement disorder in which case sensorimotor areas such as the posteroventral pallidum have
been stimulated or if they are considered to be a compulsion or a failure of inhibition wherein
associative/limbic areas have been targeted [13]. The thalamus and GPi have been the most widely
stimulated with a combination of targets used in some studies. A summary of the results of open
label trials is presented in Table 1, and blinded trials in Table 2. The outcome measures in these
studies relate to tics or co-morbidities and include the Yale global tic severity scale (YGTSS) [14] as
well as the Modified Rush video rating scale (MRVRS) [15] which measure tic frequency, severity and
impairment levels. The Yale Brown Obsessive Compulsive scale (Y-BOCS) [16] assesses the severity of
OCD/OCB symptoms whilst measures of quality of life, anxiety and depression commonly include
the Gilles de la Tourette quality of life (GTS-QOL) scale [17] State Trait Anxiety Inventory (STAI) and
Beck depression inventory (BDI), respectively, which have been validated for use in TS.
3.1. Thalamic Targets
Motor patterns in TS are postulated to result in part from an increased thalamocortical drive
due to inappropriate activation of striatal neurons [18]. There is an excitatory feedback loop from the
thalamus to the striatum originating in the CMPf and midline thalamic nuclei [19], which are the most
common thalamic targets for TS DBS.
The first report of DBS for the treatment of refractory TS by Visser-Vandewalle, used the same
thalamic nuclei (centromedian-parafasciucular complex (CM/Pf), and ventral oral internus nuclei
(Voi)) that Hassler and Dieckmann had targeted in stereotactic ablation in 1970. This individual was
a 42 years old male who subsequently experienced a 90% improvement in his tics at 12 months [20]
although using stimulation parameters with extremely high charge density, in comparison to those
used in Parkinson’s disease. In 2003, the same group reported three patients including the above who
showed a 72%–90% improvement in tics over a follow up of between eight months and five years [21].
In two of three patients the co-morbidities of SIB and OCD were also no longer present. The main
adverse effects reported were either a reduction or increase in sexual drive in two patients along
with reduced energy levels. In the larger series of 18 patients who were followed up between 3 and
18 months [22] YGTSS improvement varied between 24% and 79% in 15 of 18 patients with a concurrent
improvement in co-morbidities. A longer follow up study [23] of 15 males after five to six years showed
a mean YGTSS improvement of 73% and YBOCS of 42%. Adverse effects included a scalp erosion due
to compulsive picking, and an abdominal haematoma. These and other open label studies [24–38] are
outlined in Table 1 and strongly indicated that thalamic stimulation may have a beneficial therapeutic
role in TS for both tic severity as well as comorbid symptoms.
However, the results of two randomised controlled trials showed a more variable response.
In 2007, the anterior part of the CMPf complex was targeted in five male patients, with only a mean
improvement in tics of 17% in the YGTSS when blindly comparing ON vs. OFF stimulation. However,
three of the five responded with a 50% average reduction of tics following open label stimulation at
three months, though no biomarker could distinguish responders from non-responders. Measures of
OCD, depression and anxiety demonstrated a trend towards improvement, with a 44% increase in the
YBOCS whilst one patient experienced a psychotic episode [39]. A more recent double blind crossover
study targeted the CM-Spv-Voi assessing 6 male patients who were randomly assigned to three months
on stimulation and three months off or vice versa. At a group level improvement in tic control during
the off and on condition was 2.8% and 39.4% respectively. After one year open label follow up, these
levels were maintained at 49.2% on YGTSS and 35.5% on the MRVRS [40].
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Table 1. Summary of open label trials.
Study Target Sample Size, Sex(Age, Years)
Follow up
(Months) Stimulation Parameters
Tic outcome (Improvement
in YGTSS or MRVRS) Comoribidity Outcome Adverse Effects/Comments
Vandewalle et al.
(1999) [20],
Visser-Vandewalle
(2003) [21]
CMPf, SPv Voi Three males(42, 28, 45) 60, 12, 8
Bipolar all contacts 100 Hz, 210 µs, 2.4 V
right, 2.2 V left; Right double monopolar
65 Hz, 210 µs, 3 V; left monopolar 100 Hz,
210 µs; Right monopolar 2.8 V, 130 Hz,
210 µs; left one monopolar 2.4 V, 100 Hz 200 µs
90%, 72%, 83% OCD and SIBdisappeared in all 3.
A slight sedative effect in all three;
2 had increased or decreased libido.
Diederich et al. (2005) [41] pvGPi One male (27) 14 Monopolar 2 V, 185 Hz, 60 µs 73% (previous YGTSS 83)
No apparent change in the
mild compulsions of the
patient. Significant reduction
of anxiety/depression.
Small symptomatic haematoma
right pallidum bradykinesia of
left extremities
Flaherty et al. (2005) [42],
Shields et al (2008) [43]
Anterior capsule
CMPf, SPv Voi
One female (37),
same patient
operated at
different target
18, 3 Bipolar 4.1 V, 185 Hz, 210 µs,7 V, 90 µs, 185 Hz YGTSS 25%, 32%
Self-injury stopped (previous
retinal detachment led to
blindness in one eye), but
vision stabilized post DBS
Electrode breakage therefore same
patient had stimulation at different
target. The AC site caused altered
mood and impulse control
disturbance.
Ackermans et al. 2006 [24] CMPf, Voi pvGpi One male (45), onemale (27) 12
Monopolar 6.4 V, 130 Hz, 120 µs bilaterally;
Monopolar 3.1 V, 170 Hz, 210 µs bilaterally
Tics 20 to 3/min, Tics 28 to
2/min
Obssessions and compulsions
(measured by the revised
Padua inventory) improved
by 62% in the ON than OFF
condition
CMPf patient is the same as in
Vandewalle study- he experienced
vertical gaze palsy and decreased
libido. Both patients complained of
reduced energy.
Kuhn et al. 2007 [44] NAC, internalcapsule One male (26) 30 Tetra monopolar 90 µs, 130 Hz, 7 V
41% with YGTSS, 50%
MRVRS (Previous YGTSS 90
and MRVRS 18)
Reduction in SIB, reduction in
OCD by 52% based on
Y-BOCS
No significant adverse effects
Bajwa et al. 2007 [25] CMPf, SPv Voi One male (48) 24 Bipolar 2 V, 130 Hz and 90 µs 66% (Previous YGTSS score35.5 and overall 83) YBOCS improved 75%
Approximately 14 programming
sessions required over 2 years.
No serious adverse effects.
Shahed et al. 2007 [45] pvGPi One male (16) 6 Monopolar 5 V, 160 Hz right,145 Hz left, 90 µs 84% (YGTSS)
YBOCS improved 69% (only
obsessions not compulsions). No surgical adverse effects
Dehning et al. 2008 [46] pvGPi One female (44) 12 Monopolar 4.2 V, 145 Hz, 210 µs YGTSS 88%
Patient did have SIB
including self-biting and
beating but outcome
not reported.
Complaints of depression.
Vertigo and stomach aches in first few
months. No serious adverse effects.
Zabek et al. 2008 [47] Right NAC One male (31) 28 Not reported 80% (15-minutevideotaped exams) None reported Unilateral right side only.
Neuner et al. 2009 [48] NAC One male (38) 36 Double monopolar 6 V, 145 Hz, 90 µs YGTSS 44% mRVTRS 58% YBOCS 56%
Rapid IPG depletion-2 replacements
in 36 months. Incidental finding
was that patient no longer
wanted to smoke.
Dueck 2009 [49] pvGPi One male (16) 12 Monopolar 4 V, 130 Hz, 120 µs No improvement
Co-morbidity was severe
mental retardation which was
not affected
Not reported
Servello et al. 2008 [22] CMPf Voi 15 males, 3females (17–47) 3-18 Bipolar 2.5–4 V, 90–120 µs, 130 Hz YGTSS 65% None reported
Transient stimulation induced
vertigo, poor scalp incision healing
due to repetitive touching requiring
body shield.
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Table 1. Cont.
Study Target Sample Size, Sex(Age, Years)
Follow up
(Months) Stimulation Parameters
Tic outcome (Improvement
in YGTSS or MRVRS) Comoribidity Outcome Adverse Effects/Comments
Servello et al. 2009 [50]
CMPF +
ALIC/NA in 3,
1 had only
ALIC/NA
Three males,
one female
(25, 31 ,37, 47)
10–26 3 monopolar, 1 bipolar 4–4.5 V, 130–160 Hz,150–180 µs
Variable, mostly slight
improvement in tics Sight improvement in OCD None reported
Servello et al. 2010 [26]
Total 79
procedures
36 patients)
CMPf/Voi (67)
pvGPi
(2)ALIC-NA (10)
25 males, 6
females (17–57).
4 additional
patients received
leads in multiple
targets and one in
ALIC/NA
3–48 At last follow up 2–5 V, 90–140 µs, 60–180 Hz YGTSS 47% meanimprovement
17% mean
improvement in YBOCS
2 patients had stimulator switched
off, reporting unsatisfactory results,
2 had surgical revision of pulse
generator due to infection, and one
had hardware failure.
Martinez-Torres et al.
2009 [51] STN One male (38) 12 Monopolar 3 and 3.2 V, 130 Hz, 60 µs 76% Not reported
Patient also had Parkinson’s disease
which was the indication for DBS
in STN
Martinez-Fernandez et al.
2011 [52]
pvGPi (2), amGPi
(2), pvGPi (1) (then
changed to
anteromedial
region after
18 months)
4 males (21–60),
1 female (35) 3–24
PL GPi: Monopolar 2.5 V, 150 µs, 170 Hz,
2.5 V, 60 µs, 130 Hz; AM GPi: Monopolar
4.2 V, 60 µs, 160 Hz, Monopolar 4 V, 210 µs,
130 Hz; PL then AM GPi: Bipolar 3.6 V, 60 µs,
20 Hz for both
Anteromedial group: MRVRS
54% , Posterolateral group
(3 patients, with one
experiencing worsening
symptoms and responders
average 37% improvement).
YGTSS 38% improvement
versus 20% for amGPi
and pvGPi.
YBOCS mean change of 26%
at last follow up
Complaints of agitation in 1, anxiety
in 2, weight gain in 1, infection in 1
requiring repeat removal of battery.
Idris et al. 2010 [27] CMPf, Voa 1 male (24) 2 3.5 V, 120 µs, 130 Hz No scales reported, but ticsnoted to improve Not reported
Postoperative bilateral subcortical
haematomas attributed to low
factor XIIIA
Ackermans et al. 2010 [28] CMPf, SPv, Voi 2 males (42,45) 72–120
Amplitude L1, 8 R1, 5 130 Hz, 90 µs
Amplitude L8, 5 R8, 5 100 Hz 150 µs At
long-term follow up
Patient 1 (5 years) tic
improvement 90.1%,
maintained at 10 years
(92.6%). In patient 2, after
8 months 82% slightly
decreased at 6 years (78%).
Video tic rating scale used
measuring vocal and motor
tics/10minutes.
Not reported, but in one
patient “psychopathology“
reported to remain.
Compulsions said to have
disappeared in both patients.
In one patient with
depression, only slight
decrease after surgery.
Both patients reported reduced
energy. Both experienced traction of
the lead in neck. One patient
experienced a decrease in erectile
function whilst the other had
increased sexual drive. Both reported
some visual blurring. One patient
reported decreased verbal fluency
and learning.
Burdick et al. 2010 [53] ALIC/NA One male (33) 30 Not reported
YGTSS 15% reduction at
6 months and thereafter until
30 months of last follow up
remained unchanged.
Initially had mild tics with
a pre-operative MRVRS
score of 5.
Not reported No reported adverse effects.
Kaido et al. 2011 [19] CMPf One male (20) ,twofemales (19, 21) 14–21
Tetrapolar bilateral 2.3 V, 210 µs, 130 Hz;
Tetrapolar Left 2.1 V, right 2.3 V, left 210 µs,
right 180 µs, 130 Hz; bilaterally Tripolar
Right 2.6 V, left 2.5 V, 180 µs, 80 Hz
Tics (52%–71%) Social
impairment (56%–71%) Not reported No reported side effects.
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Table 1. Cont.
Study Target Sample Size, Sex(Age, Years)
Follow up
(Months) Stimulation Parameters
Tic outcome (Improvement
in YGTSS or MRVRS) Comoribidity Outcome Adverse Effects/Comments
Kuhn et al. 2011 [29] Vop-Voa-Voi(unilateral)
One male (39), one
female (27) 12
Bipolar 4.5 V, 130 Hz, 120 µs; Bipolar 3.1 V,
90 Hz, 120 µs
YGTSS 75%–100% MRVRS
77%–100% BDI-no negative impact
Reduced verbal fluency at one year
in both patients.
Dehning et al. 2011 [54]
(one patient previously
reported in Dehning
2008 [46])
pvGPi
Three females
(25–44),
one male (38)
5–13
4.2 V, 4 V, 3.8 V; 210 µs, 150 µs, 150 µs,
145 Hz, 130 Hz, 130 Hz (3 females) 3.5 V,
180 Ms, 130 Hz
2 patients responders (64%
and 88% improvement
YGTSS) 2 patients
non-responders 1 female
2 male
Not reported
Lead revision was done in
a non-responder without
improvement.
Dong et al. 2012 [55] pvGpi(unilateral R) Two males (41, 22) 12 Quadripolar, 3.5 V, 2.8 V, 90 µs, 160, 130 Hz YGTSS 53.1%–58.5% None reported No apparent adverse effects.
Cannon et al. 2012 [56] amGPi 8 males (22–50),3 females (18–34) 4–30
Quadripolar, initial stimulation 1 V, 60 µs,
130 Hz, adjusted at follow ups
YGTSS motor 48% vocal
56.5%
Mean YBOCS reduction 59%,
HDRS 74%, GTS-QLS 102%
Complications from hardware
malfunctions in 3 (due to SIB, MVA,
and unknown). 1 patient did not
tolerate DBS and switched it off.
Anxiety in 2 patients
Duits et al. 2012 [30] CM-Spv-Voi One male (21) 23 Not reported
YGTSS- worse with DBS
Pre-op-42 Stim OFF-12 Stim
on-39
Y-BOCS Pre-op: 20 Stim
OFF-8 Stim ON-7
Severe post-operative complications
including psychogenic paroxysmal
hypertonia.The patient may have had
a somatoform disorder, that may
contra-indicate DBS.
Savica et al. 2012 [31] CMPf 2 males, onefemale (17, 17, 35) 1
17 years old males: Bipolar 3.7 V, 120 µs,
117 Hz; Monopolar 2.5 V, 90 µs, 130 Hz.
35 years old female: Bipolar 4.1 V, 120 µs,
107 Hz
YGTSS 70% mean
improvement
No formal assessment, but
co-morbid symptoms
appeared stable or slightly
improved.
Adverse effects related to
stimulation such as mild
paraesthesias but corrected with
programming changes.
Okun et al. 2013 [32] CM (scheduledstimulation)
3 females, 2 males
(28–39) 6 Not reported
YGTSS 19% mean
improvement mRVRS 36%
mean improvement
YBOCS, HDRS, QOLAS did
not improve. No serious side effects.
Porta et al. 2012 [23] Cm-Pfc-Voa 15 male, 3 females(17–47) 5–6 years 2.5–4 V, 60–120 µs, 130 Hz YGTSS 73%
YBOCS 42% (p = 0.003),
STAI-46%, BDI−55%
One patient developed poor healing
of scalp scar due to compulsion to
touch, the other developed
abdominal haematoma where pulse
generator was located. Majority had
some minor side effects if voltage> 4
such as vertigo or blurring of vision.
Motlagh et al. 2013 [33] Midline thalamic 4 males (16–44) 6–95 0.1–5 V, 60–120 µs, 60–200 Hz(4 bipolar one tripolar)
YGTSS- Greater improvement
in the 2 younger patients
(67%–85%), compared to
older patients (7%–20%).
YBOCS-100% improvement in
on patient but minimal
change or worsening in
others, HDRS and HARS-no
change
44 year old male picked
compulsively at chest and cranial
incisions so DBS was removed due to
infection. 42 year old male had DBS
system removed due to lack of
therapeutic effect.
Dong et al. 2014 [57] pvGpi 1 male (33) 39 Monopolar 2.8 V, 90 µs, 130 Hz (frequencythen reduced to 65 Hz 33 months)
YGTSS 92.9% at 33 and
39 months
YBOCS went from 18 to 0HAS
and HDS markedly reduced
Supports that low frequency
stimulation may be an optional
therapeutic strategy in some patients
Zhang et al. 2014 [58] pvGpi 12 males (16–34),1 female (21) 13–80 Not reported
YGTSS Mean 52.1%
(13–80 months).
GTS-QOL improved by
a mean of 45.7% (range,
11.0%–77.2%).
Not reported
Sachdev et al. 2014 [59] amGPi 14 males,3 females (17–51) 8–46 Mean at follow up: 4.14 V, 95.2 µs, 139.4 Hz
Overall 48.3% reduction
motor tics, 41.3% in phonic,
1 month 70.6% of patients had
>50% reduction in YGTSS
YBOCS average 62%
improvement (p = 0.001), 39%
improvement in GTS-QOL
(p < 0.001)
Lead breakage in 4 patients, one
patient had infection, 2 transient
anxiety, 1 dizziness, 1 poor balance.
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Table 1. Cont.
Study Target Sample Size, Sex(Age, Years)
Follow up
(Months) Stimulation Parameters
Tic outcome (Improvement
in YGTSS or MRVRS) Comoribidity Outcome Adverse Effects/Comments
Huasen et al. 2014 [60] amGPi One female (19) 12 Bipolar 2.9 V, 180 Hz, 180 µs YGTSS 55% improvement Not formally assessed
Patient had a cervical cord contusion
secondary to violent cervical tics,
with DBS used to preserve limb
function and led to improvement in
her neck extension tics
Zekaj et al. 2015 [38] CMPf, Vo 1 male (17) 84 Not reported At 12 months YGTSS 58.2% Not reported
5 years post surgery DBS removed,
and patient had stabilized despite
stimulation. 2 year later continues
stable. Symptoms may have resolved
spontaneously. However, supports
DBS in younger patients.
Huys et al. 2016 [34]
Ventro- anterior
and ventrolateral
motor parts of
thalamus
Three female, five
male (19–56) 12 1.3–3.7 V, 80–130 Hz, 60–150 µs
YGTSS and mRVRS at last
follow up average 58%
In 5 no OCD at baseline,
2 mild and 1 severe.
No significant effect on OCD
comorbidity. Significant effect
on quality of life
improvement.
One patient had mild infection of
subcutaneous pulse generator one
patient had disturbance of eye
motility, tremor of lower jaw.
1 patient had suicidal thoughts,
1 dysarthria.
Smeets et al. 2016 [61] Anterior GPi
Three males and
two females
(35–57)
5–38 Tetrapolar 2.2–5.6 V, 180-360 µs, 100–180 Hz YGTSS 71.5% average
In the three patients with
baseline OCB (12%, 35%
and 100%).
Two males had previous CMPf
stimulation but due to side effects
such as gaze disturbance, switched to
GPi after 6 and 8 years after infection
with IPG replacement. Other adverse
effects included apathy in 2 patients,
weight loss and agitation in 1 patient
Cury et al. 2016 [35] CMPf One male (23) 18 Not reported YGTSS 70.5% Subscoreimpairment 60%
Patient did not have OCD
53% improvement on hospital
anxiety scale (HAS)
None reported
Servello et al. 2016 [36],
Testini et al. 2016 [37]
Vo-Cm-Pf-30,
Vo-Cm-Pf and
NA-ALIC-2,
NA-ALIC (in
3 patients as single
target, 3 as rescue
therapy) amGPi
(1 patient and 2 as
rescue) CMPf
14 females,
34 males (total 48),
37 included in
final analysis
(17–57) 18 males,
3 females (17–46)
Up to 4 years
2–91
130 Hz initally in all patients, 60–120 µs,
2.5–4.5 V Bilateral quadripolar, specific
parameters not reported
For remaining 37 patients
Mean postoperative decrease
in YGTSS 63% Reduction of
more than 50% seen in 78.4%
patients Average YGTSS 54%
(46% motor, 52% vocal and
59% impairment). All but two
patients reported marked
reduction in tic severity and
quality of life
35 OCD, 25 both OCD and
depressive disorder.
In 4 patients with
moderate/severe depression,
BDI improved by 45%, in the
other 2 only slightly or
inconsistently. All patients
had psychiatric
co-morbidities but outcome
not reported.
In 11 patients the device was
removed due to inflammatory
complications or poor compliance
and these were not included in final
analysis. NA-ALIC was the single
target in 3 patients, joint target in
another 3, and rescue for further
3 patients. PvGPi targeted in one
patient who then required rescue
surgery in NA-ALIC. 12 patients had
skin erosions requiring surgical
intervention. 1 patient underwent
wound revision due to scalp erosion
and wound infection. Three years
before, one patient had pallidal DBS
with no apparent benefit.
Postsurgical adverse effects reported
on neuropsychological evaluation
included occipital headache, and
memory loss (including temporary
anterograde amnesia)
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Table 2. Summary of randomised trials.
Study Target Sample Size, Sex(Age, Years) Follow up
Stimulation
Parameters
Effect on Tics
Severity/YGTSS or
MRVRS
Effect on Comorbidity Adverse Effects/Comments
Maciunas et al.
2007 [39] CMPf, Voi Five males (18–34) 3
Variable polarity 3.5–3.6 V,
90–210 µs,130–180 Hz
Double blind
comparison during first
4 weeks showed a 17%
improvement.
At 3 months 44% (mean)
Non-responders with
4.3%–260% tic
exacerbation
Mean score improvements: YBOCS
44%, BDI-2 60%, Hamilton anxiety
scale, (HAS) 51%
One patient experienced acute psychosis during
randomised period which was successfully treated.
Overall three responders and two non-responders
Houeto et al.
2005 [62], Welter et al.
2008 [63]
CMPF and
anteromedial
GPi
Two females, one male
(36, 30, 30) 60, 27, 20
CMPf: double
monopolar 1.5–1.7 V,
60 µs, 130 Hz, Gpi:
Single or double
monopolar 1.5–3.5 V,
60 µs, 130 Hz
YGTSS cross-over
period, (a)-AmGPi:
(65%, 96%, 74%,
(b)-CMPf: 30%, 40%,
64%, (c)-Gpi and CMPF
43%, 60%, 76% (after
60 months)
One patient previously had major
depressive disorder and
self-injurious behaviours and
impulsiveness. Depressive mood,
anxiety and impulsiveness tended to
decrease with thalamic and pallidal
stimulation but not paillidal
sitmulation alone. None of the
patients had OCD.
Reduced libido in one patient having thalamic
stimulation. Lethargy, anxiety reported under pallidal
stimulation and vertigo under higher intensity
stimulation; arm paraesthesia under thalamic. Pallidal
better than thalamic stimulation and both better than
sham stimulation.
Ackermans et al.
2011 [40] CM-Spv-Voi
6 males (completed full
trial) (35–48 years) 36
1.3–7 V, 60–210 µs,
70–130 Hz. Monopolar
stimulation in three
patients and bipolar
stimulation in the other
three patients.
YGTSS at blinded ON
compared to OFF
stimulation was
significantly lower
(37%). After one year
49% and MRVRS 35%.
No significant difference found
between the behavioural disorders
and mood in the ON and OFF
stimulation conditions.
One small haemorrhage ventral to electrode, one
infection of pulse generator, subjective gaze
disturbances which resolved after 6 months; all patient
reported reduced energy levels. All patients when
further questioned had subtle changes in oculomotor
function, from visual disturbance to blurred vision and
fixation problems, with no objective abnormalities
detected with investigations. One younger patient with
very severe SIB and life-threatening tics developed
hypertonia, mutism and repeated fainting which
needed extensive diagnostic evaluation- she was not
randomised and considered loss to follow up. Only two
patients completed the full 3 months on and of
stimulation periods.
Kefalopoulou et al.
2015 [64]
AmGPi
(13 patients),
pvGPi
(2 patients
due to
dystonic
features).
11 males 4 females
(25–55 years), 14 randomly
assigned 13 completed
assessments in both blinded
periods. All 15 received
stimulation in
open-label phase
20–60
In blinded phase,
9 patients had
monopolar and double
monopolar in 4
YGTSS from off to on
stimulation during
blinded crossover
period was 15.3%.
Increased to 40.1% in
open label phase
YBOCS-modest non-significant
improvements Significant
improvement in BDI GTS-QOL 38.9%
2 patients experienced infection of hardware requiring
removal of leads and pulse generator with antibiotic
treatment who were re-implanted 22 months later.
One patient experienced deterioration of tics and
hypomanic behaviour during on-stimulation periods,
requiring stimulation parameter alterations and
benzodiazepine treatment. 23 non-serious adverse
events occurred, 15 of which resolved. During blinded
phase, 6 patients had no clear benefit (<10%
improvement in YGTSS) but most of these had more
significant improvement in open label phase when
parameters could be optimized. In open-label phase,
4 patients had less than 20% improvement n YGTSS.
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3.2. Globus Pallidus Internus (GPi)
The GPi is considered to be functionally segregated into an anteromedial region which is part
of the associative/limbic loop of the cortico-striato-thalamo-cortical circuit, while the posteroventral
region is involved in the motor loop of the parallel circuit. However, there is much convergence of
both limbic and motor inputs in both segments of the GPi [65]. Therefore, there has been much debate
as to which sub-region might respond best to DBS for TS. The posteroventral target is familiar territory
to functional neurosurgeons as it has been stimulated in other hyperkinetic movement disorders, such
as Parkinson’s disease (PD) and various forms of dystonia.
3.2.1. Posteroventral GPi
The results of open label studies of DBS of the posteroventral GPi region in TS
patients [24,41,45,46,49,52,54,55,57,58] are also listed in Table 1. The range of tic improvement has been
20%–92.9% at 6–39 months follow up [41,45,46,52,54,55,57], with serious side effects including a small
haemorrhage in the right GPi at surgery resulting in a persistent bradykinesia of the left hand in one
27 year old male [41] and complaints of depression [46]. In a four patient cohort [52], two patients were
non-responders and two experienced an improvement in YGTSS of up to 88%, whilst in a long-term
outcome study of 13 patients YGTSS improved by 52.1% with a wide range of 4.3%–83.6% over a mean
follow up of 13–80 months) [58]. Stimulation in a 16 year old boy with TS and severe mental retardation
led to lack of symptom improvement, attributed to his severe co-morbidity [49]. Despite the variable
response at this target it may be preferred in patients with dystonic tics [66].
3.2.2. Anteromedial GPi
The rationale for targeting the anteromedial GPi region is based on the associative-limbic
connections that may impact the underlying urge driving the expression of motor and phonic tics.
A summary of the results of open label trials is also presented in Table 1 [52,56,59–61] with the amGPi
demonstrating tic improvement ranging from 38% to 71.5% [52,56,59–61] in patients followed up
between 4 and 46 months, with anxiety reported as an adverse effect [56,59].
However, when evaluated using a randomised crossover trial methodology in 15 patients,
comparison of blinded ON stimulation vs. OFF stimulation periods showed a mean YGTSS
improvement of only 15.3% although with substantial variability between patients. With long-term
follow up assessment, patients showed a 40.1% improvement in tics and 38.9% improvement in quality
of life [64] leading to discussion about factors which may influence the outcome of DBS surgery when
evaluated using blinded trial methods [67].
3.3. Other Targets
The Subthalamic nucleus (STN), External Globus pallidus (GPe), Anterior limb of
Internal capsule (ALIC) and Nucleus Accumbens (NA) have been less frequent targets for
stimulation [26,36,42–44,47,48,50,51,53,54,68]. The result of STN stimulation has only been reported
in one patient who had both PD and TS with DBS resulting in a 97% improvement in tics along with
relief of PD symptoms [51]. One male patient stimulated in the GPe region showed a 70.5% increase in
YGTSS and a 75% improvement in anxiety [68]. Although limited by study design and sample size,
the above results certainly suggest that the STN and GPe show promise as targets of stimulation and
warrant further study.
The NA and ALIC have been used as a target in treatment-resistant OCD and have been chosen
as potential stimulation targets in some circumstances owing to the frequent OCD comorbidity seen in
TS [69]. Open label studies have shown tic improvement of between 25% and 45% [42–44,48,50] at up
to 34 months follow up with adverse effects including rapid internal pulse generator depletion in one
patient requiring 2 replacement in 36 months [48]. However, in one case report there was no benefit
from NA stimulation [47].
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3.4. Comparative Studies
In a randomised crossover study, three patients had electrodes placed in both the thalamus and
the anteromedial GPi, stimulation resulting in a YGTSS improvement of 65%–96% for amGPi, 30%–64%
for CMPf and 43%–76% in combination stimulation. Follow up for as long as 60 months in 1 patient
demonstrated maintenance of tic improvement. Pallidal stimulation appeared to be more effective for
tic reduction than thalamic or even combination stimulation. However, depressive mood, anxiety and
impulsiveness were not affected by pallidal stimulation alone, whilst they showed improvement in
thalamic or combination stimulation. The thalamic and pallidal targets gave rise to varying adverse
effects with the former including arm paraesthesia and reduced libido whilst the latter included
increased anxiety [62,63].
The ALIC, which has been used for sterotactic lesioning in OCD patients and contains fibers that
travel between the orbitofrontal cortex and the anterodorsal thalamus was stimulated in a 37 year
old female with TS. This resulted in a 25% improvement on the YGTSS, but caused apathy or
hypomania as side effects. The target was subsequently switched to the CMPf of the thalamus [42,43]
resulting in a YGTSS improvement of 32% with cessation of SIBs that had led to retinal detachment.
In a four patient cohort, two patients who had previous surgery at the CM-Pf-Vo, subsequently
had ALIC/NA stimulation as rescue surgery with combined stimulation demonstrating superior
tic reduction (82.6% than ALIC/NA only (68.1%)) [43]. These comparative studies can inform whether
specific targets have a differential effect on tics and co-morbid symptoms which could impact target
selection for TS patients with different co-morbidities.
3.5. Clinical Outcome and Targets
In a recent systematic review the thalamic targets of DBS were found to improve YGTSS scores by
an average of 47.62% p < 0.001 with comparable results for GPi (55.32%), whilst the ALIC/NA regions
showed a 44% improvement (p = 0.017) albeit in a smaller number of patients [70]. Direct comparisons
between targets generally also indicate a lesser effect with ALIC stimulation [50,53]. The co-morbidity
outcome across targets revealed a median 31.25% reduction in YBOCS and 38.89% in BDI, but
without any statistically significant difference in the outcome of tics or co-morbidity. It should be
considered that clinical outcomes are attributed to the target yet the anatomical brain regions ultimately
stimulated by DBS depend on precise electrode placing, stimulation parameters, as well as individual
anatomical variation [70]. The development of computer models using electrode location and extent
of current spread has enabled investigation of the electric field distribution in individual patients
using proton-density magnetic resonance imaging (MRI) scans. In one such study of five patients
who had DBS targeting the amGPi, patient-specific stimulation confirmed this region to be the main
stimulation field. However, three patients showed possible extension into GPe and internal capsule
and in two patients with clear extension into the anterior GPe, there was a superior clinical effect.
This highlights the importance of analysing the exact position of effective stimulation contacts and
correlating outcome with patient specific stimulation fields in order to obtain more valid results about
optimal target [71].
Although no definitive predictive factors for improved tic outcome have been identified, a positive
correlation was observed between pre-operative YGTSS impairment score and tic reduction following
amGPi DBS (p = 0.01), whilst the opposite effect was seen for pre-operative YGTSS tic severity
and outcome following thalamic DBS. Furthermore there was no correlation between severity of
co-morbidity symptoms or with stimulation parameters and tic outcome [70]. This meta-analysis
did find a trend towards younger age and improved outcome, suggesting that the neurobiological
underpinnings of TS are better impacted by stimulation in the younger population. Interpretation
is limited by pooling of results from sub-regions of the thalamus or ventral striatum which could
be improved by using individual co-ordinates and settings though these are not always available.
These findings nevertheless remain informative and suggest that higher YGTSS impairment scores,
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tic severity, patient age and choice of preferred target should all be considered in the selection of
patients for DBS.
3.6. Inclusion and Exclusion Criteria
The suitability of DBS in TS patients depends on many factors yet there is much variability
around specific inclusion and exclusion criteria across studies. Typically, core criteria focus on accurate
diagnosis, high tic severity (typically a YGTSS score >35/50) and resistance to at least three different
pharmacological agents [72]. Although psychiatric co-morbidity is a common component of TS, motor
and vocal tics should be the main source of disability [7]. In addition, realistic expectations of DBS
outcome and adequate social support [22], as well as compliance in attending appointments for
outcome assessment or alteration of parameter settings is crucial when selecting patients for DBS.
These should all be considered in a multidisciplinary team setting including a neurologist, psychiatrist,
neurosurgeon and psychologist.
Exclusion criteria typically include major psychiatric disorders, pregnancy, current substance
abuse or dependence and severe cognitive impairment, (supported by a study showing a lack of benefit
in a 16 year old boy with TS and mental retardation undergoing DBS, although the outcome of this
single case report should not be over-interpreted [49]). Other factors warranting exclusion include
structural abnormalities on MRI, general contra-indications for surgery and patients with somatoform
disorder [61] which have also been outlined in the European guidelines for TS [73]. Some centres
have also used age as an exclusion criteria, restricting DBS to patients over 18 or 25 [73], based on
the premise that TS may subside into adulthood and that there are ethical implications for placing
patients under potentially unnecessary surgical risk. Nonetheless, adolescence is a crucial period
for social, emotional and educational development and preventing younger patients with severe
debilitating TS receiving treatment could impact negatively on independence and wellbeing into adult
life. This is supported by beneficial reports in younger patients including a 17 year old with SIBs
that prevented full time school attendance who showed markedly improved social integration post
DBS [37]. Consequently, recent recommendations argue against strict age criteria and suggest that
younger patients should be reviewed on a case by case basis, involving a local ethics committee.
3.7. Adverse Effects
Adverse effects can be classified into procedure or stimulation related events with some
stimulation effects varying between targets. Stimulating the thalamic CM-Spv-Voi region has been
associated with gaze disturbances or visual symptoms which are less often seen when targeting motor
regions of the thalamus [34]. Other adverse effects include increased or decreased libido, which can
result from modulating certain parts of intra-laminar thalamic nuclei involved in controlling sexual
function [74]. In addition, arm paraesthesia, dysarthria and a case of psychosis have been reported.
Stimulation of the pvGPi has been associated with increased anxiety, depression and memory
impairment [33], whilst that of the amGPi has also been related to higher anxiety levels, dyskinetic
limb movements and a case of hypomania [64]. Stimulation of the ALIC/NA was linked to side effects
such as depression, hypomania, as well as a suicide attempt reported in an NA patient with known
depressive episodes. The adverse effects of apathy, fatigue, dizziness and weight changes are more
common across targets and in many instances adjustment of the stimulation parameters can diminish
or eradicate these but target selection should aim to limit their effects.
Procedure related adverse effects mostly centre around hardware malfunction and infections with
the latter appearing to be higher in TS compared to other movement disorders. This was suggested by
a retrospective study of 272 DBS patients, 39 of whom were treated for TS and showed an overall 3.7%
infection rate whilst for TS this was 18 [75]. The higher rate of infection in TS patients was attributed
to the compulsive picking at surgical scars in some patients [75] though altered immune function
has also been postulated including lower T cell count [76], dysgammaglobulinemia, or an altered
immunomodulatory effect of dopamine [77], though this requires further investigation.
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3.8. Mechanisms of DBS Action in TS
DBS has demonstrated improvement in patient symptoms across targets yet much remains
to be elucidated about its mechanism of action. Some studies have investigated the role of
DBS in the dopaminergic modulation of striatothalamic pathways, supported by the postulated
hyper-dopaminergic innervation in TS pathology and the use of dopamine antagonists in TS treatment.
The first report of modulation of dopaminergic transmission with DBS was in a 22 years old patient who
had undergone bilateral thalamic stimulation with a resultant improvement in tics [78]. Six months
post surgery [8F] fallypride (FP) positron emission tomography (PET) scans, which quantified the
striatal and extrastriatal dopamine 2/3 (D2/3) receptors, showed a 16.3% decrease in dopamine
binding potential during on-stimulation compared to off-stimulation conditions, suggesting that DBS
may indirectly cause a decrease in dopamine release. In addition, there was an increase in D2/3
receptor availability in the baseline on condition compared to healthy control subjects (n = 20) based
on a published control group. A further study using FP PET scans on three patients receiving thalamic
DBS demonstrated similar results in dopamine binding during DBS [79]. Although these studies are
limited by small sample size and potential anaesthetic effect, they indicate that dopamine modulation
may be a component of the therapeutic impact of DBS.
It had previously been shown using electroencephalography that premotor potentials did not
precede simple motor tics in TS suggesting that the cortex was not their site of origin [80,81] though
more recent contradictory findings have also been published [82]. Microelectrode recordings in
thalamic nuclei during DBS surgery has typically shown a burst-firing pattern with an interburst
interval ranging from 0.12 to 0.4 s within the low frequency (delta/theta) range (2.5–8 Hz) [83].
Similar results were obtained in a study that demonstrated oscillatory activity at low frequencies [84],
which has also been observed in other hyperkinetic movement disorders, such as dystonia [85]
suggesting that low-frequency activity and decreased thalamic beta activity could contribute to
the pathophysiology of TS. This is supported by correlation with clinical phenotype in a patient
who had few tics but severe OCD showing significantly fewer low-frequency oscillations than in
local field potentials (LFPs) recorded in patients with severe tics. Further, increased gamma activity
(25–45 Hz) recorded from the CM in awake patients with TS (n = 5) correlated with tic improvement
and demonstrated that DBS increases the power of LFP gamma oscillations [86]. Therefore, shifting
basal ganglia thalamic oscillation power from low to high frequency may be one of the effects
of DBS in TS patients, supported by the correlation between increased CM gamma activity and
clinical tic reduction [86]. Short-term neuronal mechanisms of DBS in TS have also been investigated
using primate models of basal ganglia-mediated motor tics [87]. High frequency stimulation in the
anteromedial GPi was shown to significantly reduce the amplitude of tic related phasic changes in the
pallidum most likely caused by cellular activity temporally locking with the stimulation pulse [87].
Neuroplasticity is also being recognised as relevant to the effects of DBS supported by the
reported shift in magnitude of long-latency response components across stimulation blocks [87].
However in a study investigating thalamic LFP recordings in a 48 years old male with Tourette
syndrome 12 months after DBS, LFPs remained in the low frequency range as observed a few days after
initial DBS implantation, suggesting that DBS may not cause a persistent change in LFP oscillation
pattern [88] though this requires investigation in more patients. Evidence has implicated microglia
in the modification of synaptic connections and plasticity which could contribute to functionally
immature control networks typical of that seen in TS. The role of DBS in altering the immunobiology
of the brain in TS is an interesting avenue of research [89].
Mechanisms of DBS in TS should continue to be explored as they inform both the pathophysiology
of the disorder and ways in which DBS delivery can be optimized in patients. When considering the
search for an optimal target, the high interconnectivity of basal ganglia structures means it is likely
that stimulation in one area will have profound downstream or upstream effects in others and rather
than the target being a specific focus of pathology, it may instead block propagation of aberrant signals
through a local network [87]. As DBS currents spread through anatomical connections, it may be
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useful to consider the effect of target stimulation on these different brain networks through a variety
of imaging techniques. Functional magnetic resonance imaging (fMRI) compatible DBS systems could
be used to map cortical-subcortical circuits [90] and patient specific tractography activation models
(TAMs) could identify white matter pathways and monitor the projections being activated by DBS in
individual patients [91]. Resting state functional connectivity MRI, which has previously been used
to identify thalamic DBS targets based on connectivity to brain regions in tremor could be applied in
a similar way to tics in TS [92]. These methods may help motivate a shift to the stimulation of specific
brain networks and potentially customise treatment for varying patient phenotypes.
3.9. Adaptive DBS in TS
Further research into neurophysiological recordings in TS patients can also inform the potential
future application of adaptive rather than continuous DBS which may be particularly relevant due
to the paroxysmal nature of TS [93]. An adaptive DBS system would allow the pathological neural
activity of patients to be used as feedback through variables, such as LFPs recorded by DBS electrodes,
informing when tics will arise and leading to a responsive alteration in stimulation to suppress their onset.
The finding that increased gamma band activity and reduced alpha band power in the CM
complex of the thalamus correlated with superior clinical outcome [86] could be the starting point
for developing specific neural markers correlating with tic onset. Moreover, the GPi has been seen to
exhibit low frequency oscillations that precede the electromyographic recording of tics by 50 ms or
more, and may mark the premonitory urge of motor tics [88], whilst LFP recordings in ALIC/NA, have
shown high beta power oscillations, a potential physiological indicator of OCD activity [88]. However,
the reliability of feedback algorithms and the accuracy of correlation of variables such as LFPs with
clinical symptoms requires much investigation, particularly as the latter can differ between tic types
and individual patients [94] A proof of principle study showed the beneficial effects of scheduled
DBS in TS patients [32] and though a closed loop system was not employed it may provide the
foundation for applying neuromodulatory approaches. The benefits of an adaptive DBS system pertain
to the reduced energy expenditure leading to a prolonged battery life [95], as well as a reduction in
stimulation related side effects, such as fatigue or anxiety, potentially further improving patient quality
of life.
Nonetheless, the use of adaptive DBS remains highly experimental in all conditions, not least until
a consistent neurophysiological biomarker for tic urge is identified and issues of sustained efficacy and
potential side effects have been thoroughly investigated in future trials and studies.
4. Discussion
Stimulation applied to different cortico-basal ganglia thalamic network structures appears to
improve motor and non-motor symptoms in TS. However, over-interpretation of ‘between target
comparisons’ of these results is unwise as most data are derived from case reports and small
prospective series with wide variability in methodology. Although more double-blind controlled
studies are required, designing these to ensure adequate optimization of stimulation settings as well as
maintenance of patient and investigator blinding can be a challenge [67].
Therefore, study design and patient selection should be carefully considered in the future in order
to investigate the relative strength of treatments across studies.
Establishing an optimal target has been controversial as the precise pathophysiology of TS is not
yet elucidated and stimulated structures have high interconnectivity. To date, the most commonly used
targets have been the thalamus and GPi, which have shown variable but overall promising results.
Many patients with electrodes targeting the GPi will have electrode trajectories that also straddle the
GPe. Reviewing the data in Tables 1 and 2, the optimal stimulation parameters often include the more
dorsal electrodes therefore potentially also preferentially delivering stimulation to the GPe fibres.
Only single studies have investigated the STN and the GPe despite demonstrating beneficial
effects in tic reduction. Further, the STN is known to have an excitatory influence on the GPi, which
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could be manipulated to affect both the limbic and sensorimotor circuits to a greater extent than using
the GPi or thalamus alone. Further insight into the cortico-subcortical networks stimulated by DBS
through different imaging modalities will further inform optimal targeting.
Looking closer at patient specific factors related to variability of response could help reveal
predictive factors for improved outcome. Results of a meta-analysis suggesting that higher
pre-operative YGTSS impairment and younger age in patients targeted in the GPi region, correlated
with better tic outcome in the may also inform future inclusion and exclusion criteria. Furthermore,
correlating clinical outcome to specific fields of stimulation based on patient specific computer models,
may contribute to a more accurate mapping of the optimal target within structures like the GPi/GPe.
Study outcomes have focused on tic reduction using rating scales, such as the YGTSS, and although
these are validated and include measures of overall impairment, they are not always an accurate
reflection of tic impact on self-esteem and socio-professional life. The social integration of TS patients
should be a considered a vital aim of the DBS procedure, determined not only by a reduction in tics,
but often more importantly, by that of co-morbid symptoms. Consequently, it is crucial that studies
uniformly use scales such as the GTS-QOL, STAI and BDI in order to compare quality of life and
co-morbidity outcomes across targets. Further, supportive accounts from caregivers can also increase
the accuracy of clinical evaluation.
In order to further assess the efficacy of thalamic DBS there is a need for larger, multi-centre trials
with careful consideration of optimal trial design to ensure the outcome of this intervention can be
objectively assessed. One proposal would be to perform a direct comparison of thalamic (CMPf) DBS
against anteromedial GPI/GPe DBS with the latter electrodes deliberately straddling both GPi and
GPe targets. Intraoperative and post-operative recordings from externalized electrodes will continue
to be informative regarding the neurophysiological changes associated with tics and OCD/OCB.
Confirmation of dopaminergic receptor occupancy post DBS using functional imaging techniques
would be useful.
To compare the clinical efficacy of two targets requires a sufficiently long period of time for
resolution of surgical swelling and wound healing and stimulation parameters can require long
periods before considered optimized. Objective confirmation of efficacy must also include an off
stimulation assessment, brief if necessary to allow the impact of stimulation to be distinguished from
placebo effects. There is now a worldwide consortium of clinicians including functional neurosurgeons
interested in DBS and the design of such future trials are the subject of ongoing discussions.
5. Conclusions
Despite variable outcomes between patients, DBS for TS has shown much promise across targets.
The careful design of randomised trials, use of comparative studies and imaging modalities in DBS
systems can inform target selection. Considering that the ultimate aim of this procedure is the social
integration of patients, future studies should continue to address the treatment of both tics and
co-morbidities. Further elucidating the mechanisms of DBS action can help enable its optimization,
inform the pathophysiology of TS and future potential applications of adaptive DBS.
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